MORRISTOWN, N.J., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (PTX), a specialty pharmaceutical company, announced today that the Company will report financial results for the third quarter and nine months ended September 30, 2018, after the market close on Thursday, November 8, 2018. Pernix management will also host a conference call at 4:30 pm Eastern Time to discuss the results.
|Date:||Thursday, November 8|
|Time:||4:30 PM ET|
|Toll free (U.S.):||866-548-4713|
About Pernix Therapeutics Holdings, Inc.
Pernix Therapeutics Holdings, Inc. (the “Company”) is the parent company of Pernix Therapeutics, LLC, a specialty pharmaceutical business focused on acquiring and commercializing prescription drugs, primarily for the U.S. market. Pernix Therapeutics, LLC is currently focused on the therapeutic areas of Pain and Neurology, and has an interest in expanding into additional specialty segments. Pernix Therapeutics, LLC promotes branded products to physicians through its internal sales force. The Company’s wholly-owned subsidiaries, Macoven Pharmaceuticals, L.L.C., and Cypress Pharmaceuticals, Inc., market a portfolio of generic products.
To learn more about Pernix Therapeutics, visit www.pernixtx.com.
LifeSci Advisors, LLC